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Abstract: Human metapneumovirus (HMPV) is a major pediatric respiratory pathogen with 23 currently no specific treatment or licensed vaccine. Different strategies to prevent this infection have 24 been evaluated, including live-attenuated vaccines (LAV) based on SH and/or G protein deletions.
25
This approach showed promising outcomes but has not been evaluated further using different viral 26 strains. In that regard, we previously showed that different HMPV strains harbor distinct in vitro 27 fusogenic and in vivo pathogenic phenotypes, possibly influencing the selection of vaccine strains.
28
In this study, we investigated the putative contribution of the low conserved SH or G accessory 29 proteins in such strain-dependent phenotypes and generated recombinant wild type (WT) and SH-30 or G-deleted viruses derived from two different patient-derived HMPV strains, A1/C-85473 and 31 B2/CAN98-75.
32
The ΔSH and ΔG deletions led to different strain-specific phenotypes in both LLC-MK2 cell and 33 reconstituted human airway epithelium models. More interestingly, the ΔG-85473 and especially 34 ΔSH-C-85473 recombinant viruses conferred significant protection against HMPV challenge and 35 induced immunogenicity against a heterologous strain. In conclusion, our results show that the viral 36 genetic backbone should be considered in the design of live-attenuated HMPV vaccines, and that a 37 SH-deleted virus based on the A1/C-85473 HMPV strain could be a promising LAV candidate as it 38 is both attenuated and protective in mice while being efficiently produced in a cell-based system.
Introduction

45
Human metapneumovirus (HMPV) is a worldwide cause of acute respiratory tract infections 46 (ARTI) among children, the elderly and immunocompromised individuals [1, 2] . HMPV infections 47 share many features with those of the human respiratory syncytial virus (HRSV), also belonging to 48 the Pneumoviridae family [3, 4] . Despite the important clinical burden in infants and young children, 49 no licensed vaccine or specific and potent antiviral are currently available. While several HRSV 50 vaccine candidates have already entered clinical trials [5] , some HMPV candidates have shown the 51 potential to progress towards clinical evaluation stages [6] . In that regard, different HMPV vaccine 52 strategies have been evaluated in animals, from formalin-inactivated vaccine, leading to enhanced 53 disease [7] , to the elaboration of protein-based recombinant vaccines or live-attenuated vaccines 54 (LAV) [6] . Among them, LAV have shown the potential to elicit both humoral and mucosal immunity 55 and mimic natural viral replication routes, and they are therefore considered as highly suitable for 56 HMPV pediatric immunization strategies [8] .
57
HMPV viruses are divided into two main phylogenetic lineages (A and B), which are further 58 divided into at least two sub-lineages (A1, A2a/A2b, B1 and B2) [9] [10] [11] [12] [13] . The HMPV genome is 59 composed of a negative single stranded RNA molecule of approximately 13 kb in length, containing 60 eight genes encoding for nine different proteins [14, 15] , including three surface glycoproteins (F, G, 61 SH). The F glycoprotein is the major HMPV antigen [16] and leads to both attachment and fusion of 62 viral particles to the target cell [17] . In contrast, the exact role of G and SH glycoproteins is still a 63 matter of debate. Indeed, the F protein of HMPV has been shown to bind not only the cellular integrin 64 αVβ1 receptor but also glycosaminoglycans (GAGs), such as heparan sulfate, hence being able to 65 substitute to the virus GAG-mediated attachment function once exclusively attributed to the G protein 66 [18] [19] [20] [21] . Nonetheless, a role of the G protein was also suggested in the host cell response to infection 67 [22] [23] [24] . For instance, stimulation of the retinoid-acid inducible gene 1 (RIG-I) signaling pathway 68 was reported with a recombinant HMPV (rHMPV) lacking the G protein (ΔG) in vitro, which led to 69 increased NF-κB activation and enhanced cytokine secretion [22] . On the other hand, the SH protein 70 has been shown to alter the NF-κB pathway [25] and also to form a viroporin complex at the cell 71 membrane [26].
72
The G and SH proteins have been considered for a long time as "accessory" non-essential 73 proteins for HMPV replication [27] , as illustrated by recombinant HMPV viruses lacking either G, 74 SH or both genes that can replicate efficiently in vitro and in vivo [28] . Moreover, the contribution of 75 G and SH proteins to HMPV antigenicity, as well as the attenuation phenotype associated to G-deleted 76 virus, led to consider such modified viruses as potential LAV candidates [16, 27] . However, the 77 achievement of such perspectives is nuanced by the fact that all previous studies were based on a 78 unique HMPV backbone, notably the prototypical CAN97-83 strain from the A2 sub-lineage. In that 79 regard, many HMPV subtypes co-circulate each year with high genetic diversity among A and B 80 subtypes, particularly in the case of the less conserved G and SH proteins, with approximately 37% 81 and 59% amino acid sequence homologies between subtypes, respectively [9, 14] . In parallel, we and 82 others previously demonstrated that HMPV viruses diverge in their in vitro and/or in vivo phenotypes 83 in a strain-dependent manner, notably by considering the HMPV F and G proteins and their functions 84 [18, [29] [30] [31] [32] [33] .
85
In this context, we generated recombinant wild type (WT) and SH-or G-deleted viruses (ΔSH 86 and ΔG respectively) from two patient-derived HMPV strains (A1/C-85473 and B2/CAN98-75) and 87 compared the respective functional impacts of SH and G deletions. In this context, we observed 88 different strain-specific phenotypes both in LLC-MK2 cells and reconstituted human airway 
137
For experimental virus entry assays, confluent LLC-MK2 cells were inoculated at a MOI of 0.5 138 after being placed on ice for 5 min and washed with cold PBS. The binding of virus to cells proceeded 139 for 2 h on ice until the inoculum was replaced by fresh infection medium. Cells were incubated for 5 140 min, 30 min, 1 h or 2 h at 37°C and 5% CO2 to allow virus entry into cells, medium was then removed and citrate buffer (40 mM sodium citrate dihydrate, 10 mM potassium chloride, 135 mM sodium 142 chloride, pH 3.0) was added to inactivate any remaining extracellular virus, as previously described 143 [38] . Cells were washed in PBS and incubated at 37°C in fresh medium during 24 h. Infected cells 144 were quantified by GFP detection in flow cytometry and values were normalized to condition without 145 viral inactivation.
147
Infection of reconstituted human airway epithelium TCID50/ml at 4 dpi, ΔSH-CAN98-75 virus showed reduced replication as early as 2 dpi, with a 24 h 214 delay to reach peak titer (1.95×10 5 TCID50/ml) (Figure 1B) . A significantly more attenuated 215 phenotype was observed with the ΔG-CAN98-75 virus, for which the highest viral titer measured 216 (5.72×10 4 TCID50/ml at 7 dpi) was delayed and 1.2 log10 lower than that of the WT (Figure 1B) .
217
This differential replication among the three CAN98-75-based recombinant viruses was also 218 illustrated by representative fluorescent microscopy images of infected LLC-MK2 cells at 3 dpi, 219 notably considering the extent of viral spread and GFP positive cells (Figure 1D) . On the contrary, 220 no such important differences in replication properties were observed between the two deleted C-221 85473-derived recombinant viruses and their WT counterpart (Figure 1C) . Peak viral titers of 222 approximately 1×10 5 TCID50/ml for both the C-85473-WT and ΔSH-C-85473 viruses, or a peak of 223 4.22×10 4 TCID50/ml for the ΔG-C-85473 virus were reached by 4 dpi (Figure 1C) 
241
Considering the different phenotypes of rHMPV virus derived from the A1/C-85473 and 242 B2/CAN98-75 strains and the "attachment" role attributed to the G protein, we further evaluated the 243 specific impact of the G and SH gene deletions on the binding and the entry of the rHMPV to LLC-244 MK2 cells (Figure 2) . While the rCAN98-75 virus showed progressive binding kinetics, reaching a 245 maximum of 68% GFP-positive cells after 3h of adsorption, the ΔSH-CAN98-75 virus showed faster 246 binding in the first hour, yet achieving a maximal plateau of 47% by 2h (Figure 2A) . Not surprisingly, 247 the deletion of the G protein significantly hampered the binding capacity of the ΔG-CAN98-75 virus, 248 with a mean of ̴ 10% GFP-positive cells all throughout the experiment (Figure 2A) . In contrast, and 249 as observed for the replicative capacities, the binding ability of the C-85473-derived viruses was not 250 significantly hampered at 3h by the gene deletions: 57% for ΔSH-and 54% for ΔG-C-85473 versus 251 43% for the WT rC-85473 ( Figure 2B) .
Regarding cell entry kinetics, the ΔSH-CAN98-75 virus seemed to enter LLC-MK2 cells slower 253 than its WT counterpart and the ΔG-CAN98-75 virus, with 24% of ΔSH-CAN98-75-infected cells 254 after 120 min compared to 43% for WT and ΔG-CAN98-75 viruses (Figure 2C) . Conversely, the 255 three rC-85473-derived viruses showed rather rapid cell entry kinetics with more than 36% of infected 256 cells after 60 min. Interestingly, both ΔSH-and ΔG-C-85473 viruses showed higher entry properties 257 compared to their WT counterpart after 120 min with 66%, 79% and 57% of infected cells, 258 respectively (Figure 2D ). previously showed that this model is permissive to HMPV infection and globally mimics the in vivo 276 host respiratory epithelium response to such infection [36] . In line with these results, we observed 277 that both rCAN98-75 and rC-85473-derived viruses are also able to infect, replicate and spread within 278 the HAE (Figure 3) .
260
279
Based on the GFP expression pattern within the infected HAE at 5 dpi, we observed that the 280 ΔSH-CAN98-75 spread more efficiently than its WT counterpart, at the difference of the ΔG-CAN98-281 75 virus, which appeared dramatically impaired (Figure 3A) . These results were confirmed by the 282 quantification of N gene copies number within the infected epithelium. In line with the fluorescent 283 microscopy observations, the viral quantifications at 5 dpi indicated a significant 6-fold higher viral 284 replication of the ΔSH-CAN98-75 virus and 3.3 log10 lower values for the ΔG-CAN98-75 virus in 285 comparison to the WT CAN98-75 virus (Figure 3B) . At the difference, the ΔSH-C-85473 virus acted 286 similarly to its WT counterpart, considering both spread pattern and viral replication within the HAE 287 model (Figure 3C-D) . Besides, the spread of the ΔG-C-85473 virus seemed to be more affected in 288 HAE model than in LLC-MK2 monolayer (Figure 3C) 
303
These results indicate that rHMPV harbour different strain-dependent replicative properties in 304 HAE model (Figure 3) compared to the LLC-MK2 model (Figure 1) . In the CAN98-75 viral We therefore infected mice intra-nasally with 5×10 5 TCID50 of either ΔG-C-85473 or ΔSH-C-318 85473 viruses, the equivalent non-lethal dose inoculum needed to induce a significant (>10%) weight 319 loss with the WT rC-85473 virus at 7 dpi (Figure 4A) . Similar to the mock (non-infected) group and 320 in contrast with the WT rC-85473, neither weight loss nor clinical signs were observed in the ΔG-C-321 85473 and ΔSH-C-85473-infected groups during the 14-day follow-up. In contrast, lung viral titers 322 at 5 dpi were comparable between WT and deleted viruses, as determined by both cell culture and 323 molecular methods (Figures 4B-C) . In agreement with the weight curves, lower histopathological 
339
We then evaluated the capacity of ΔSH-and ΔG-C-85473 attenuated viruses to protect mice 340 from a lethal viral challenge. Upon viral challenge with 1×10 6 TCID50 of rC-85473 virus, mock-341 immunized mice showed significant (50%) HMPV-associated mortality, starting on day 5 post-342 challenge and spanning until day 8 post-challenge, with mean weight loss of 11% (peak after 7 days) 343 ( Figure 5A) . Conversely, both ΔSH-and ΔG-C-85473-immunized mice groups, as well as control 344 rC-85473-immunized mice, were completely protected from HMPV-associated mortality induced by 345 viral challenge and showed mean maximum weight losses of 3-4% of their initial weight (peak at day 346 2 post-challenge) (Figure 5A-B ). 
348
359
Similarly to the rC-85473 WT virus, the protection induced by immunization with ΔG-C-85473 360 and ΔSH-C-85473 was associated with the induction of high neutralizing antibody titers at 21 days 361 after challenge, particularly in the case of ΔSH-C-85473 (Table 2) . Importantly, neutralization assays 362 also showed that induced antibody responses were effective in neutralizing WT patient-derived strains 363 as well as the heterologous CAN98-75 HMPV B strain ( Table 2) . In line with these results, we were 364 unable to recover HMPV viruses or detect viral genome from the lungs of any of the three different 365 rHMPV-immunized groups on day 5 post-challenge (Table 2) . However, we still recorded reduced 366 but significant pulmonary inflammation in WT-and ΔG-C-85473-immunized mice, compared to 367 mock-immunized mice (scores of 7.5 and 7 versus 9.5, respectively), whereas ΔSH-C-85473-368 immunized mice had a much lower histopathological score of 2.5 (Figure 5C) . Indeed, ΔSH-C-369 85473-immunized group showed reduced interstitial and perivascular inflammations and no bronchial 370 and intra-alveolar inflammation (Figure 5C) . In contrast to mock-immunized mice, none of the 371 rHMPV-immunized groups developed pulmonary edema after viral challenge (Figure A1) . we measured high expression levels of cytokines, corresponding to an acute response to high dose of 384 viral challenge, as it is the case for RANTES (19 000pg/ml, Figure 6A ). Interestingly, higher levels 385 of several cytokines/chemokines (IL-10, IL-6, G-CSF, TNF-α) were measured in the lungs of ΔSH-386 immunized mice in comparison with WT and ΔG-immunized groups (Figure 6A) . In accordance with 387 the absence of detectable virus (Table 2 ) and the decreased histopathological scores (Figure 5C) , the 388 level of most of the measured cytokines lowered 5 days post-challenge (Figure 6A) . In addition, we 389 observed an important recruitment of leukocyte populations in rHMPV-immunized groups from day 390 1 after challenge, which persisted for at least five days later (Figure 6B) . Of note, the ΔSH-391 immunized group showed significant enhanced infiltration of leukocytes in lungs 5 days post-392 challenge, particularly T CD4+, T CD8+, and B cell populations (Figure 6B ).
393
Overall, our results suggest that deleted rC-85473 viruses harbor distinct but attenuated and (Figure 1) , in line with a previous study advocating the putative "accessory role" of these two gene-427 products [27] . However, we observed that viral replication in LLC-MK2 cells was significantly 428 decreased when G and, to a lesser extent SH, were deleted from the B2/CAN98-75 virus (Figure 1) .
429
Such a distinct replication phenotype between A and B viruses (A1/C-85473 and A2/CAN97-83 vs 430 B2/CAN98-75) suggests that the HMPV genetic background might influence the impact of gene 431 deletions on viral fitness. This is of particular importance if we consider efficient production yield 432 (i.e. comparable to that of the WT virus) as a major requirement for the development of a LAV 433 candidate.
434
We also previously showed that C-85473 and CAN98-75 strains induce very different fusogenic (Figure 4) . Accordingly, we recently showed that the SH deletion in 464 the C-85473 backbone limits the virus-induced activation of NLRP3-inflammasome both in vitro and 465 in vivo, and subsequently reduces inflammation and pathogenicity in HMPV infected mice [34] .
